Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

Company Overview - Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with significant unmet medical needs [2] - The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist targeting key underlying causes of MASH [2] - Rezdiffra is the first and only medication approved by both the FDA and European Commission for treating MASH with moderate to advanced fibrosis (F2 to F3) [2] - An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c) [2] Upcoming Events - The company will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 2:30 P.M. ET, with a live webcast available for access [1]